We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+30.02%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$201M
AUM Growth
+$31.2M
Cap. Flow
+$76.3K
Cap. Flow %
0.04%
Top 10 Hldgs %
56.18%
Holding
53
New
12
Increased
15
Reduced
7
Closed
9

Top Buys

Rank Stock Value
1
NVLN
Novelion Therapeutics Inc. Common Shares
NVLN
+$7.46M
2
IMMU
Immunomedics Inc
IMMU
+$4.86M
3
OCUL icon
Ocular Therapeutix
OCUL
+$3.8M
4
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$2.25M
5
CTMX icon
CytomX Therapeutics
CTMX
+$2.24M

Top Sells

Rank Stock Value
1
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$12.4M
2
NGNE icon
Neurogene
NGNE
+$3.95M
3
MGNX icon
MacroGenics
MGNX
+$3.48M
4
OMER icon
Omeros
OMER
+$2.63M
5
CLSD
Clearside Biomedical
CLSD
+$2.41M

Sector Composition

Rank Sector Weight
1 Healthcare 98.69%
2 Miscellaneous 1.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BPMC
1
DELISTED
Blueprint Medicines
BPMC
$35.2M 17.51%
880,000
– –
AXGN icon
2
Axogen
AXGN
$2.78B
$20.6M 10.25%
1,970,000
– –
KYNB
3
Kyntra Bio
KYNB
$32.4M
$8.13M 4.05%
13,200
– –
NVLN
4
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$7.84M 3.9%
+730,000
New +$7.46M
CMRX
5
DELISTED
Chimerix, Inc.
CMRX
$7.75M 3.86%
1,215,000
+45,000
+4% +$255K
AGIO icon
6
Agios Pharmaceuticals
AGIO
$2.05B
$7.59M 3.78%
130,000
– –
TVRD
7
Tvardi Therapeutics
TVRD
$24M
$7.08M 3.52%
10,694
-2,500
-19% -$1.34M
TBPH icon
8
Theravance Biopharma
TBPH
$885M
$6.63M 3.3%
180,000
+21,800
+14% +$696K
IMMU
9
DELISTED
Immunomedics Inc
IMMU
$6.21M 3.09%
+960,000
New +$4.86M
MNTA
10
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$5.87M 2.92%
440,000
+110,000
+33% +$1.72M
CTMX icon
11
CytomX Therapeutics
CTMX
$745M
$5.87M 2.92%
340,000
+170,000
+100% +$2.24M
CDXS icon
12
Codexis
CDXS
$182M
$5.62M 2.8%
1,170,000
– –
SBBP
13
DELISTED
Strongbridge Biopharma plc.
SBBP
$5.61M 2.79%
1,180,000
+20,000
+2% +$61.3K
LOXO
14
DELISTED
Loxo Oncology, Inc
LOXO
$5.47M 2.72%
130,000
+5,000
+4% +$206K
OCUL icon
15
Ocular Therapeutix
OCUL
$2.38B
$5.1M 2.54%
550,000
+456,400
+488% +$3.8M
ADMS
16
DELISTED
Adamas Pharmaceuticals
ADMS
$5.08M 2.53%
290,000
+5,000
+2% +$85.2K
PRTA icon
17
Prothena Corp
PRTA
$467M
$4.86M 2.42%
87,100
+4,600
+6% +$242K
EGRX
18
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$4.15M 2.06%
50,000
– –
HROW icon
19
Harrow
HROW
$1.44B
$3.59M 1.79%
860,500
+140,500
+20% +$365K
SAGE
20
DELISTED
Sage Therapeutics
SAGE
$3.2M 1.59%
45,000
+10,000
+29% +$586K
NDRM
21
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$3.19M 1.59%
120,000
+5,000
+4% +$124K
ENTA icon
22
Enanta Pharmaceuticals
ENTA
$402M
$3.08M 1.53%
100,000
+10,000
+11% +$311K
SGMO
23
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$3.02M 1.5%
581,000
+181,000
+45% +$726K
PDSB icon
24
PDS Biotechnology
PDSB
$12.2M
$2.55M 1.27%
14,000
– –
FOMX
25
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$2.48M 1.23%
500,000
+5,000
+1% +$48.1K
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q1 2017 Portfolio in Review

As of Q1 2017, Opaleye Management held 53 positions worth $201M, up 18% from $170M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Opaleye Management's Q1 2017 filing shows 12 new, 15 increased, 7 reduced and 9 closed positions. Its largest new stake was Novelion Therapeutics Inc. Common Shares: 730,000 shares worth $7.84M. The largest sale was Ariad Pharmaceuticals Inc, an estimated $12.4M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

  • Opaleye Management's largest Q1 2017 buy was Novelion Therapeutics Inc. Common Shares: 730,000 shares worth $7.84M.
  • Opaleye Management added most to Ocular Therapeutix in Q1 2017, an estimated $3.8M increase.
  • Opaleye Management's biggest Q1 2017 reduction was Neurogene, cutting an estimated $3.95M.
  • Opaleye Management fully exited Ariad Pharmaceuticals Inc in Q1 2017, selling an estimated $12.4M.
  • Opaleye Management's ten largest holdings make up 56% of its $201M portfolio in Q1 2017.
  • Opaleye Management opened 12 new positions and closed 9 in Q1 2017.
  • Opaleye Management's portfolio value rose 18% quarter-over-quarter to $201M.

Based on Opaleye Management's 13F filing for Q1 2017, filed 15 May 2017.